Drug intelligence / Profile preview

OVM-100

Development stage: Preclinical
Lead developer: Oxford Vacmedix
Modality: Vaccines & Immunotherapeutics

Overview

OVM-100 is a therapeutic cancer vaccine developed by Oxford Vacmedix using their proprietary recombinant overlapping peptide (ROP) platform, targeting HPV antigens for the treatment of cervical cancer and head and neck cancer. It stimulates broad and strong T-cell immunity by presenting overlapping peptide fragments of HPV proteins to enhance cellular immune responses against cancer cells. The vaccine is intended for use as monotherapy or in combination with immune-oncology agents, with preclinical development ongoing and plans for Phase 1 trials.[2][3][7][8]

Beyond the preview

Go deeper on OVM-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVM-100.

Explore the full profile